Â鶹AV

Introduction

The aim of the 2nd Â鶹AV – BMCS Fragment-Based Drug Discovery meeting will be to continue the focus on Case Studies in Fragment-Based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programs. These case studies will include successful examples from all types of Fragment-Based approaches, including High concentration, NMR, SPR and X-ray screening. This conference is suitable for scientists from any discipline with an interest in expanding their knowledge and experience of FBDD

Downloads

• Fragments 2009 Circular FINAL.pdf

Sponsorship & supporting organisations

AstraZeneca

Venue

AstraZeneca

AstraZeneca, Alderley Park, Cheshire, United Kingdom

Contact information

Elaine Wellingham
United Kingdom
01275 853311
Contact us by email

---